AU2011306917B2 - Breast cancer therapeutics - Google Patents

Breast cancer therapeutics Download PDF

Info

Publication number
AU2011306917B2
AU2011306917B2 AU2011306917A AU2011306917A AU2011306917B2 AU 2011306917 B2 AU2011306917 B2 AU 2011306917B2 AU 2011306917 A AU2011306917 A AU 2011306917A AU 2011306917 A AU2011306917 A AU 2011306917A AU 2011306917 B2 AU2011306917 B2 AU 2011306917B2
Authority
AU
Australia
Prior art keywords
cancer
rankl
inhibitor
mammary
rank
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011306917A
Other languages
English (en)
Other versions
AU2011306917A1 (en
Inventor
Josef Penninger
Daniel Schramek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMBA Institut fur Molekulare Biotechonologie GmbH
Original Assignee
IMBA Institut fur Molekulare Biotechonologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43498569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011306917(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IMBA Institut fur Molekulare Biotechonologie GmbH filed Critical IMBA Institut fur Molekulare Biotechonologie GmbH
Publication of AU2011306917A1 publication Critical patent/AU2011306917A1/en
Application granted granted Critical
Publication of AU2011306917B2 publication Critical patent/AU2011306917B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2011306917A 2010-09-22 2011-09-22 Breast cancer therapeutics Ceased AU2011306917B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10178346.2 2010-09-22
EP10178346A EP2433644A1 (en) 2010-09-22 2010-09-22 Breast cancer therapeutics
PCT/EP2011/066511 WO2012038504A2 (en) 2010-09-22 2011-09-22 Breast cancer therapeutics

Publications (2)

Publication Number Publication Date
AU2011306917A1 AU2011306917A1 (en) 2013-04-04
AU2011306917B2 true AU2011306917B2 (en) 2015-01-29

Family

ID=43498569

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011306917A Ceased AU2011306917B2 (en) 2010-09-22 2011-09-22 Breast cancer therapeutics

Country Status (15)

Country Link
US (2) US10143747B2 (enExample)
EP (2) EP2433644A1 (enExample)
JP (2) JP6133778B2 (enExample)
KR (1) KR20130118870A (enExample)
CN (1) CN103384530A (enExample)
AU (1) AU2011306917B2 (enExample)
BR (1) BR112013006673A2 (enExample)
CA (1) CA2811556A1 (enExample)
CL (1) CL2013000801A1 (enExample)
IL (1) IL225442A0 (enExample)
MX (1) MX2013003076A (enExample)
NZ (1) NZ608207A (enExample)
PH (1) PH12013500543A1 (enExample)
RU (1) RU2013118325A (enExample)
WO (1) WO2012038504A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3458090A1 (en) * 2016-05-19 2019-03-27 Probiocon GmbH Anti-cancer combination treatment
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098362A2 (en) * 2001-06-06 2002-12-12 Immunex Corporation Use of rank antagonists to treat cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
NZ332995A (en) 1997-04-15 2000-07-28 Snow Brand Milk Products Co Ltd A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
BR9808545A (pt) 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6790823B1 (en) * 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20040167072A1 (en) 2001-05-11 2004-08-26 Aggarwal Bharat B. Inhibitors of receptor activator of NF-kappaB and uses thereof
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2005028633A2 (en) 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of rankl expression
WO2005060627A2 (en) 2003-12-10 2005-07-07 Auxeris Therapeutics, Inc. Methods of assessing the risk of non-traumatic bone fracture
US20080107597A1 (en) 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
EP1854458A1 (en) 2006-05-08 2007-11-14 IMBA-Institut für Molekulare Biotechnologie GmbH Use of a compound with RANKL activity
TW201019959A (en) 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098362A2 (en) * 2001-06-06 2002-12-12 Immunex Corporation Use of rank antagonists to treat cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CANON, J. et al. BONE. 1 June 2007. vol. 40, no. 6. Suppl 2, page S145. *
CANON, J. et al. CANCER TREATMENT REVIEWS. 1 January 2008. vol. 34. page 17. *
CANON, J. et al. EUROPEAN JOURNAL OF CANCER SUPPLEMENT. 1 November 2006. vol 4. no. 12. pages 166-167. *
ELLIS, G.K. et al. BREAST CANCER RESEARCH AND TREATMENT. November 2009. vol. 118, no. 1, pages 81-87. Epub 2009 Mar 24. *
HOLLAND P.M. et al. CANCER BIOLOGY AND THERAPY. 1 April 2010. vol. 9, no. 7, pages 539-550. *
LEE, R.J. BONE. January 2011. vol. 48, no. 1, pages 88-95. Epub 2010 May 31. *
LEIBBRANDT, A. & PENNINGER, J.M. EUROPEAN JOURNAL OF CLINICAL INVESTICATION, 01 October 2009. vol. 39, no. 10, pages 842-850. *
TOMETSKO, M. et al. JOURNAL OF BONE AND MINERAL RESEARCH. 1 September 2006. vol 21. no. Suppl.1, page S346. *
TOMETSKO, M. et al. Presented at the 9th International Meeting on Cancer Induced Bone Disease, Arington, VA October 28-31, 2009 2009. BONE, Pergamon Press, vol. 47, no. Suppl.2, 01 July 2010, pages S325-326. *

Also Published As

Publication number Publication date
EP2618833B1 (en) 2018-05-02
CA2811556A1 (en) 2012-03-29
US20190030161A1 (en) 2019-01-31
US20130216550A1 (en) 2013-08-22
KR20130118870A (ko) 2013-10-30
JP6133778B2 (ja) 2017-05-24
WO2012038504A3 (en) 2012-06-21
EP2618833A2 (en) 2013-07-31
NZ608207A (en) 2014-08-29
IL225442A0 (en) 2013-06-27
PH12013500543A1 (en) 2021-08-09
US10143747B2 (en) 2018-12-04
CN103384530A (zh) 2013-11-06
EP2433644A1 (en) 2012-03-28
JP2013542190A (ja) 2013-11-21
JP2017039771A (ja) 2017-02-23
WO2012038504A2 (en) 2012-03-29
MX2013003076A (es) 2013-07-29
AU2011306917A1 (en) 2013-04-04
BR112013006673A2 (pt) 2016-06-07
CL2013000801A1 (es) 2013-11-29
RU2013118325A (ru) 2014-10-27

Similar Documents

Publication Publication Date Title
AU2011306917B2 (en) Breast cancer therapeutics
Benvenuto et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors
Huang et al. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
AU2011306918B2 (en) Breast cancer diagnostics
Friel et al. Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors
Delgado-Rosas et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis
Wu et al. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms
CN105007942A (zh) 用于瘤形成治疗的组合疗法
Altinoz et al. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma
Nguyen et al. Progesterone and 1, 25-dihydroxyvitamin D3 inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F
Choi et al. Oral TGF-βR1 inhibitor Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity
JP2016501845A (ja) 前立腺がんを処置するための方法
Zhang et al. Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma
ES2755933T3 (es) Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus
EP4534093A1 (en) Pharmaceutical composition for preventing or treating cancer, containing, as active ingredient, monocytes or macrophages in which expression or activity of cd244 is inhibited
US20230174662A1 (en) Methods of treating castrate-resistant prostate cancer
Escher The Role of Dysregulated IFNα Signaling in Promoting Aromatase Inhibitor-Resistance in ER+ Breast Cancer
Rotman Strategies to enhance immunotherapy efficacy in HPV-related gynecologic (pre-) malignancies
WO2024234056A1 (en) Treatment of breast tissue
CN114980879A (zh) 用于治疗癌症的药物组合
Ghosh Nrdp1-Mediated ErbB3 Increase During Androgen Ablation and Its Contribution to Androgen-Independence
Komiya et al. Definition, mechanisms of development and current treatments of castration-resistant prostate cancer
WO2020097318A1 (en) Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues
Colombo p50 Nuclear Factor-B Overexpression in Tumor-Associated Macrophages Inhibits M1 Inflammatory Responses and Antitumor Resistance

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired